AngioDynamics, Inc. (NASDAQ:ANGO) Receives Consensus Rating of “Moderate Buy” from Brokerages

AngioDynamics, Inc. (NASDAQ:ANGO) has been assigned a consensus recommendation of “Moderate Buy” from the five ratings firms that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $19.3333.

A number of equities research analysts recently weighed in on ANGO shares. Zacks Research raised AngioDynamics from a “hold” rating to a “strong-buy” rating in a report on Friday, January 9th. Wall Street Zen cut AngioDynamics from a “buy” rating to a “hold” rating in a report on Sunday, December 21st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of AngioDynamics in a research note on Wednesday, January 21st.

AngioDynamics Trading Up 5.0%

NASDAQ ANGO opened at $10.56 on Friday. AngioDynamics has a 1-year low of $8.27 and a 1-year high of $13.99. The company has a 50 day moving average of $11.86 and a 200-day moving average of $11.13. The firm has a market cap of $435.28 million, a price-to-earnings ratio of -15.76 and a beta of 0.51.

Hedge Funds Weigh In On AngioDynamics

A number of institutional investors have recently modified their holdings of the stock. Goldman Sachs Group Inc. grew its stake in shares of AngioDynamics by 9.6% during the first quarter. Goldman Sachs Group Inc. now owns 259,226 shares of the medical instruments supplier’s stock valued at $2,434,000 after purchasing an additional 22,658 shares during the last quarter. Jane Street Group LLC boosted its position in AngioDynamics by 267.1% in the 1st quarter. Jane Street Group LLC now owns 46,803 shares of the medical instruments supplier’s stock valued at $439,000 after buying an additional 34,054 shares during the last quarter. Y Intercept Hong Kong Ltd increased its stake in shares of AngioDynamics by 890.3% in the 2nd quarter. Y Intercept Hong Kong Ltd now owns 224,514 shares of the medical instruments supplier’s stock valued at $2,227,000 after buying an additional 201,843 shares during the period. Pier Capital LLC increased its stake in shares of AngioDynamics by 40.5% in the 2nd quarter. Pier Capital LLC now owns 694,235 shares of the medical instruments supplier’s stock valued at $6,887,000 after buying an additional 200,244 shares during the period. Finally, Bastion Asset Management Inc. raised its position in shares of AngioDynamics by 46.5% during the second quarter. Bastion Asset Management Inc. now owns 959,043 shares of the medical instruments supplier’s stock worth $9,810,000 after acquiring an additional 304,217 shares during the last quarter. 89.43% of the stock is owned by institutional investors.

About AngioDynamics

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.